HOPA is committed providing high quality education that is strongly integrated with HOPA’s core passion to support pharmacy practitioners and promote and advance Hematology/Oncology Pharmacy to optimize the care of individuals affected by cancer. HOPA strives to become the destination of choice for quality education focused on creating competent hematology/oncology pharmacists with sound domain knowledge, skills and managerial acumen.  Below is the full spectrum of education offerings – you may also sort by content area, date, delivery method, and if it offers BCOP recertification credit.

Novel Immunotherapy Options for the Long-term Care of Patients with Chronic Lymphocytic Leukemia (CLL): The Role of Clinical and Specialty Pharmacists

Live Video Broadcast!

September 18, 2018
7:00 pm ET

Credits: 1.5 hours

Register Now

Faculty Presenters

Julianne Orr, PharmD, BCOP
Outpatient Oncology Clinical Pharmacist
Department of Pharmacy
Indiana University Health Simon Cancer Center
Indianapolis, Indiana

Christopher A. Fausel, PharmD, MHA, BCOP
Clinical Manager, Oncology Pharmacy    
Indiana University Health
Chairman of the Board
Hoosier Cancer Research Network
Indianapolis, Indiana

This activity is supported by educational grants from Pharmacyclics LLC. An AbbVie company; Janssen Biotech, Inc.; and CURE Media Group.

Program Overview

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia presenting in Western countries. It is defined by gradual malignant accumulation of lymphocytic cells, beginning in the bone marrow and extending into the blood, and is triggered by genomic alterations that inhibit the apoptosis of clonal B cells. Several novel immunotherapeutics target specific signaling pathways in CLL. BCR-associated kinases, such as Bruton tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3Kδ), have been successfully targeted by novel therapeutics. Other inhibitors of BCR signaling include antibodies that target CD20, CD52, and compounds that target the antiapoptotic molecule Bcl-2. Clinical and specialty pharmacists must focus primarily on managing and counseling patients with CLL and health care professionals about adverse events and novel immunotherapeutic options that are currently available.

Learning Objectives

Upon completion of this educational activity, participants will be able to:

  • Illustrate the current and novel treatment options for chronic lymphocytic leukemia (CLL)
  • Demonstrate the importance of integrating new and/or emerging CLL agents into the current treatment paradigm for CLL, including their risks related to resistance, relapse, and immune-related adverse events
  • Employ strategies that will improve communication, engagement, education, and decision making with patients with CLL and their health care providers

Target Audience




CPE Accreditation:

logo acpePharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-18-140-L01-P. The activity is available for CE credit for September 18, 2018.

Obtaining Credit:

To receive CPE credit, participants must register for the live video broadcast, complete the pretest, view the broadcast in its entirety, complete the posttest and the online activity evaluation. After successful completion of the online posttest and activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at All participants must request credit before November 18, 2018.



The following contributor has a relevant financial relationship with a commercial interest to disclose:

Julianne Orr, PharmD, BCOP
Advisory Board: Novartis

The following contributors have no relevant financial relationships with commercial interests to disclose:

Christopher A. Fausel, PharmD, MHA, BCOP

Pharmacy Times Continuing Education

Planning Staff - David Heckard; Maryjo Dixon, RPh; Eyrin Pena, MD; Olivia Mastrodonato; Susan Pordon; and Brianna Winters.

Activity Disclaimer

Pharmacy Times Continuing Education™ (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation.

Educational Disclaimer

Continuing professional education (CPE) activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

System Requirements

PC-based participants
Required: Windows 7, Vista, XP, 2003 Server or 2000
Macintosh-based participants
Required: Mac OS X 10.4.11 (Tiger) or newer

For questions about this Internet CPE activity, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
Privacy Policy and Terms of Use information:

Register Now